title: Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.
abstract: Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and advanced urothelial cancer after failure of platin-containing therapy. Since approval, the drug has been investigated in few clinical trials. Most of the currently available reports describe experiences with VFL in a daily clinical setting. This review gives a short overview on clinical experiences and clinical trials involving VFL since the approval of this drug in 2009.
authors.affiliation: University Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Rahel-Straus-Straße 10, 26133 Oldenburg, Germany.
authors.forename: Holger
authors.initials: H
authors.lastname: Gerullis
authors.affiliation: University Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Germany.
authors.forename: Friedhelm
authors.initials: F
authors.lastname: Wawroschek
authors.affiliation: University Hospital of Oncology/Haematology, Oncology Center Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Germany.
authors.forename: Claus-Henning
authors.initials: CH
authors.lastname: Köhne
authors.affiliation: HELIOS Hospital, Department of Urology, Bad Saarow, Germany.
authors.forename: Thorsten Holger
authors.initials: TH
authors.lastname: Ecke
keywords: mTCCU; metastatic urothelial carcinoma; second line; urothelial cancer; vinflunine